Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax, Azacitidine, and Homoharringtonine for Secondary AML
NCT05513131Phase 2Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2021
- Primary completion
- Sep 2023
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and homoharringtonine in acute myeloid leukemia (AML), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Percentage of participants with complete remission (CR) and complete remission with incomplete marrow recovery (CRi). Status: unknown.
02
Drugs
venetoclaxhomoharringtonine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05513131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05513131.